▶ 調査レポート

細胞培養系インフルエンザワクチンの世界市場見通し2023年-2029年

• 英文タイトル:Cell Culture-based Flu Vaccine Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが調査・発行した産業分析レポートです。細胞培養系インフルエンザワクチンの世界市場見通し2023年-2029年 / Cell Culture-based Flu Vaccine Market, Global Outlook and Forecast 2023-2029 / MRC2312MG08412資料のイメージです。• レポートコード:MRC2312MG08412
• 出版社/出版日:Market Monitor Global / 2023年12月
• レポート形態:英文、PDF、72ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥481,000 (USD3,250)▷ お問い合わせ
  Enterprise User¥721,500 (USD4,875)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートは次の情報を含め、世界の細胞培養系インフルエンザワクチン市場規模と予測を収録しています。・世界の細胞培養系インフルエンザワクチン市場:売上、2018年-2023年、2024年-2029年
・世界の細胞培養系インフルエンザワクチン市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の細胞培養系インフルエンザワクチン市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「バイアル」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

細胞培養系インフルエンザワクチンのグローバル主要企業は、CSLなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、細胞培養系インフルエンザワクチンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の細胞培養系インフルエンザワクチン市場:タイプ別、2018年-2023年、2024年-2029年
世界の細胞培養系インフルエンザワクチン市場:タイプ別市場シェア、2022年
・バイアル、充填済み

世界の細胞培養系インフルエンザワクチン市場:用途別、2018年-2023年、2024年-2029年
世界の細胞培養系インフルエンザワクチン市場:用途別市場シェア、2022年
・公共、民間

世界の細胞培養系インフルエンザワクチン市場:地域・国別、2018年-2023年、2024年-2029年
世界の細胞培養系インフルエンザワクチン市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における細胞培養系インフルエンザワクチンのグローバル売上、2018年-2023年
・主要企業における細胞培養系インフルエンザワクチンのグローバル売上シェア、2022年
・主要企業における細胞培養系インフルエンザワクチンのグローバル販売量、2018年-2023年
・主要企業における細胞培養系インフルエンザワクチンのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
CSL

*************************************************************

・調査・分析レポートの概要
細胞培養系インフルエンザワクチン市場の定義
市場セグメント
世界の細胞培養系インフルエンザワクチン市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の細胞培養系インフルエンザワクチン市場規模
世界の細胞培養系インフルエンザワクチン市場規模:2022年 VS 2029年
世界の細胞培養系インフルエンザワクチン市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの細胞培養系インフルエンザワクチンの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の細胞培養系インフルエンザワクチン製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:バイアル、充填済み
細胞培養系インフルエンザワクチンのタイプ別グローバル売上・予測

・用途別市場分析
用途区分:公共、民間
細胞培養系インフルエンザワクチンの用途別グローバル売上・予測

・地域別市場分析
地域別細胞培養系インフルエンザワクチン市場規模 2022年と2029年
地域別細胞培養系インフルエンザワクチン売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
CSL
...

This research report provides a comprehensive analysis of the Cell Culture-based Flu Vaccine market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Cell Culture-based Flu Vaccine market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Cell Culture-based Flu Vaccine, challenges faced by the industry, and potential opportunities for market players.
The global Cell Culture-based Flu Vaccine market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Cell Culture-based Flu Vaccine market presents opportunities for various stakeholders, including Public Sector, Private Sector. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Cell Culture-based Flu Vaccine market. Additionally, the growing consumer demand present avenues for market expansion.
The global Cell Culture-based Flu Vaccine market was valued at US$ 564.8 million in 2022 and is projected to reach US$ 1169.9 million by 2029, at a CAGR of 11.1% during the forecast period.
A significant driver in the Influenza Vaccine market is the growing awareness of the importance of vaccination in preventing seasonal and pandemic influenza outbreaks. As healthcare organizations and governments worldwide promote vaccination as a crucial public health measure, there is an increasing demand for influenza vaccines. Additionally, advances in vaccine research and development, including the production of more effective and broader-spectrum vaccines, are driving market growth. One of the key challenges in this market is the need for frequent vaccine updates to match evolving influenza strains. The virus undergoes genetic changes, requiring annual adjustments to vaccine formulations. This presents logistical challenges for manufacturers in terms of timely production and distribution. Vaccine hesitancy and misinformation also pose challenges by impacting vaccination rates and public perception. Lastly, ensuring equitable access to vaccines, especially in low-income and underserved populations, remains a persistent challenge in the fight against influenza.
Key Features:
The research report on the Cell Culture-based Flu Vaccine market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Cell Culture-based Flu Vaccine market.
Market Overview: The report provides a comprehensive overview of the Cell Culture-based Flu Vaccine market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Vial, Prefilled), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Cell Culture-based Flu Vaccine market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Cell Culture-based Flu Vaccine market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Cell Culture-based Flu Vaccine market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Cell Culture-based Flu Vaccine market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Cell Culture-based Flu Vaccine market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Cell Culture-based Flu Vaccine market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Cell Culture-based Flu Vaccine, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Cell Culture-based Flu Vaccine market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Cell Culture-based Flu Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Vial
Prefilled
Market segment by Application
Public Sector
Private Sector
Global Cell Culture-based Flu Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
CSL
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cell Culture-based Flu Vaccine, market overview.
Chapter 2: Global Cell Culture-based Flu Vaccine market size in revenue and volume.
Chapter 3: Detailed analysis of Cell Culture-based Flu Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cell Culture-based Flu Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Cell Culture-based Flu Vaccine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

レポート目次

1 Introduction to Research & Analysis Reports
1.1 Cell Culture-based Flu Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cell Culture-based Flu Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cell Culture-based Flu Vaccine Overall Market Size
2.1 Global Cell Culture-based Flu Vaccine Market Size: 2022 VS 2029
2.2 Global Cell Culture-based Flu Vaccine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Cell Culture-based Flu Vaccine Sales: 2018-2029
3 Company Landscape
3.1 Top Cell Culture-based Flu Vaccine Players in Global Market
3.2 Top Global Cell Culture-based Flu Vaccine Companies Ranked by Revenue
3.3 Global Cell Culture-based Flu Vaccine Revenue by Companies
3.4 Global Cell Culture-based Flu Vaccine Sales by Companies
3.5 Global Cell Culture-based Flu Vaccine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Cell Culture-based Flu Vaccine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Cell Culture-based Flu Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cell Culture-based Flu Vaccine Players in Global Market
3.8.1 List of Global Tier 1 Cell Culture-based Flu Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 Cell Culture-based Flu Vaccine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Cell Culture-based Flu Vaccine Market Size Markets, 2022 & 2029
4.1.2 Vial
4.1.3 Prefilled
4.2 By Type – Global Cell Culture-based Flu Vaccine Revenue & Forecasts
4.2.1 By Type – Global Cell Culture-based Flu Vaccine Revenue, 2018-2023
4.2.2 By Type – Global Cell Culture-based Flu Vaccine Revenue, 2024-2029
4.2.3 By Type – Global Cell Culture-based Flu Vaccine Revenue Market Share, 2018-2029
4.3 By Type – Global Cell Culture-based Flu Vaccine Sales & Forecasts
4.3.1 By Type – Global Cell Culture-based Flu Vaccine Sales, 2018-2023
4.3.2 By Type – Global Cell Culture-based Flu Vaccine Sales, 2024-2029
4.3.3 By Type – Global Cell Culture-based Flu Vaccine Sales Market Share, 2018-2029
4.4 By Type – Global Cell Culture-based Flu Vaccine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Cell Culture-based Flu Vaccine Market Size, 2022 & 2029
5.1.2 Public Sector
5.1.3 Private Sector
5.2 By Application – Global Cell Culture-based Flu Vaccine Revenue & Forecasts
5.2.1 By Application – Global Cell Culture-based Flu Vaccine Revenue, 2018-2023
5.2.2 By Application – Global Cell Culture-based Flu Vaccine Revenue, 2024-2029
5.2.3 By Application – Global Cell Culture-based Flu Vaccine Revenue Market Share, 2018-2029
5.3 By Application – Global Cell Culture-based Flu Vaccine Sales & Forecasts
5.3.1 By Application – Global Cell Culture-based Flu Vaccine Sales, 2018-2023
5.3.2 By Application – Global Cell Culture-based Flu Vaccine Sales, 2024-2029
5.3.3 By Application – Global Cell Culture-based Flu Vaccine Sales Market Share, 2018-2029
5.4 By Application – Global Cell Culture-based Flu Vaccine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Cell Culture-based Flu Vaccine Market Size, 2022 & 2029
6.2 By Region – Global Cell Culture-based Flu Vaccine Revenue & Forecasts
6.2.1 By Region – Global Cell Culture-based Flu Vaccine Revenue, 2018-2023
6.2.2 By Region – Global Cell Culture-based Flu Vaccine Revenue, 2024-2029
6.2.3 By Region – Global Cell Culture-based Flu Vaccine Revenue Market Share, 2018-2029
6.3 By Region – Global Cell Culture-based Flu Vaccine Sales & Forecasts
6.3.1 By Region – Global Cell Culture-based Flu Vaccine Sales, 2018-2023
6.3.2 By Region – Global Cell Culture-based Flu Vaccine Sales, 2024-2029
6.3.3 By Region – Global Cell Culture-based Flu Vaccine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Cell Culture-based Flu Vaccine Revenue, 2018-2029
6.4.2 By Country – North America Cell Culture-based Flu Vaccine Sales, 2018-2029
6.4.3 US Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.4.4 Canada Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.4.5 Mexico Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Cell Culture-based Flu Vaccine Revenue, 2018-2029
6.5.2 By Country – Europe Cell Culture-based Flu Vaccine Sales, 2018-2029
6.5.3 Germany Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.5.4 France Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.5.5 U.K. Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.5.6 Italy Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.5.7 Russia Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.5.8 Nordic Countries Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.5.9 Benelux Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Cell Culture-based Flu Vaccine Revenue, 2018-2029
6.6.2 By Region – Asia Cell Culture-based Flu Vaccine Sales, 2018-2029
6.6.3 China Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.6.4 Japan Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.6.5 South Korea Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.6.6 Southeast Asia Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.6.7 India Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Cell Culture-based Flu Vaccine Revenue, 2018-2029
6.7.2 By Country – South America Cell Culture-based Flu Vaccine Sales, 2018-2029
6.7.3 Brazil Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.7.4 Argentina Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Cell Culture-based Flu Vaccine Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Cell Culture-based Flu Vaccine Sales, 2018-2029
6.8.3 Turkey Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.8.4 Israel Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.8.5 Saudi Arabia Cell Culture-based Flu Vaccine Market Size, 2018-2029
6.8.6 UAE Cell Culture-based Flu Vaccine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 CSL
7.1.1 CSL Company Summary
7.1.2 CSL Business Overview
7.1.3 CSL Cell Culture-based Flu Vaccine Major Product Offerings
7.1.4 CSL Cell Culture-based Flu Vaccine Sales and Revenue in Global (2018-2023)
7.1.5 CSL Key News & Latest Developments
8 Global Cell Culture-based Flu Vaccine Production Capacity, Analysis
8.1 Global Cell Culture-based Flu Vaccine Production Capacity, 2018-2029
8.2 Cell Culture-based Flu Vaccine Production Capacity of Key Manufacturers in Global Market
8.3 Global Cell Culture-based Flu Vaccine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Cell Culture-based Flu Vaccine Supply Chain Analysis
10.1 Cell Culture-based Flu Vaccine Industry Value Chain
10.2 Cell Culture-based Flu Vaccine Upstream Market
10.3 Cell Culture-based Flu Vaccine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Cell Culture-based Flu Vaccine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer